{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:24:55Z","timestamp":1791271495636,"version":"4.1.0"},"reference-count":58,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,12,12]],"date-time":"2013-12-12T00:00:00Z","timestamp":1386806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:p>Lymphoid malignancies comprise a heterogeneous group of disorders originating from clonal proliferation of <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content> lymphocytes. Treatment of lymphoid neoplasms has traditionally been pursued with cytotoxic chemotherapy. To improve efficacy and ameliorate the adverse effects associated with classic chemotherapy, molecularly targeted therapy has been developed. At the forefront of clinical development is ibrutinib, an inhibitor of Bruton's tyrosine kinase (Btk). Btk is a protein tyrosine kinase that plays an important role in regulating <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>\u2010cell signaling. Dysregulated Btk results in uncontrolled <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>\u2010lymphocyte proliferation, differentiation, and survival. Ibrutinib is currently being studied in numerous malignancies of lymphoid origin including chronic lymphocytic leukemia, mantle cell lymphoma, non\u2010Hodgkin lymphoma, follicular lymphoma, and multiple myeloma. Thus far, ibrutinib has demonstrated very promising results in treatment\u2010naive patients as well as those with relapsed or refractory disease with an acceptable safety profile. In this article, we describe the pharmacology, efficacy, and toxicity profile of ibrutinib and depict the potential role that ibrutinib will play in the treatment paradigm of lymphoid neoplasms.<\/jats:p>","DOI":"10.1002\/phar.1366","type":"journal-article","created":{"date-parts":[[2013,12,12]],"date-time":"2013-12-12T03:22:40Z","timestamp":1386818560000},"page":"303-314","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The Promising Impact of Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, for the Management of Lymphoid Malignancies"],"prefix":"10.1002","volume":"34","author":[{"given":"Valkal","family":"Bhatt","sequence":"first","affiliation":[{"name":"Department of Pharmacy Memorial Sloan\u2010Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linh","family":"Alejandro","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of California\u2010San Diego Cancer Center San Diego California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Michael","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Memorial Sloan\u2010Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Ganetsky","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Hospital of the University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,12,12]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI66307"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2012.656199"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e32834b8943"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri953"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1155\/2001\/28962"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.4281"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"e_1_2_10_9_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.7056","article-title":"Pharmacokinetics (PK) of ibrutinib in patients with chronic lymphocytic leukemia (CLL) [abstract 7056]","volume":"31","author":"Sukbuntherng J","year":"2013","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4918"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2010.09.005"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-352492"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-212837"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0228"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386417"},{"key":"e_1_2_10_16_1","article-title":"In vivo effects of ibrutinib on BCR signaling, tumor cell activation and proliferation in blood and tissue\u2010resident cells of chronic lymphocytic leukemia patients [abstract 99.13]","volume":"120","author":"Herman SEM","year":"2012","journal-title":"Blood"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2395"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.0762"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012143432402"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.5.770"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1021"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-140582"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_2_10_25_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.187.187","article-title":"The Btk inhibitor ibrutinib (PCI\u201032765) in combination with rituximab is well tolerated and displays profound activity in high\u2010risk chronic lymphocytic leukemia (CLL) patients [abstract 187]","volume":"120","author":"Burger JA","year":"2012","journal-title":"Blood"},{"key":"e_1_2_10_26_1","article-title":"A phase I trial of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI\u201032765), in combination with rituximab (R) and bendamustine in patients with relapsed\/refractory non\u2010Hodgkin's lymphoma (NHL) [abstract 1643]","volume":"120","author":"Blum KA","year":"2012","journal-title":"Blood"},{"key":"e_1_2_10_27_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.6508","article-title":"A phase Ib\/II study evaluating activity and tolerability of BTK inhibitor PCI\u201032765 and ofatumumab in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and related diseases [abstract 6508]","volume":"30","author":"Jaglowski SM","year":"2012","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.11.2819"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2554"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147025"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp495"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_10_35_1","article-title":"Differential role of the B\u2010cell receptor pathway in diffuse large cell B cell lymphoma: temsirolimus has additive effects in combination with the BTK inhibitor PCI\u201032765 and PI3K inhibitor Cal101 but antagonizes bortezomib in GCB subtype [abstract 1664]","volume":"118","author":"Zoellner A\u2010K","year":"2011","journal-title":"Blood"},{"key":"e_1_2_10_36_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.686.686","article-title":"The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI\u201032765), has preferential activity in the ABC subtype of relapsed\/refractory de novo diffuse large B\u2010cell lymphoma (DLBCL): interim results of a multicenter, open\u2010label, phase 2 study [abstract 686]","volume":"120","author":"Wilson WH","year":"2012","journal-title":"Blood"},{"key":"e_1_2_10_37_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.156.156","article-title":"The Bruton's tyrosine kinase inhibitor ibrutinib (PCI\u201032765) is active and tolerated in relapsed follicular lymphoma [abstract 156]","volume":"120","author":"Fowler NH","year":"2012","journal-title":"Blood"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1804"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.12.037"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M708935200"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-396853"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2012.09.008"},{"key":"e_1_2_10_43_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.983.983","article-title":"The Bruton's tyrosine kinase (BTK) inhibitor PCI\u201032765 induces durable responses in relapsed or refractory (R\/R) chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): follow\u2010up of a phase Ib\/II study [abstract 983]","volume":"118","author":"O'Brien S","year":"2011","journal-title":"Blood"},{"key":"e_1_2_10_44_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.1789.1789","article-title":"Ibrutinib (PCI 32765) rapidly improves platelet counts in chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) patients and has minimal effects on platelet aggregation [abstract 1789]","volume":"120","author":"Farooqui M","year":"2012","journal-title":"Blood"},{"key":"e_1_2_10_45_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.7057","article-title":"Open label evaluation of ECG in patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib monotherapy [abstract 7057]","volume":"31","author":"Loury D","year":"2013","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_46_1","unstructured":"National Library of Medicine Bethesda MD Pharmacyclics A phase 3 study of ibrutinib (PCI\u201032765) versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia (RESONATE)"},{"key":"e_1_2_10_47_1","unstructured":"National Library of Medicine Bethesda MD Pharmacyclics A multicenter open\u2010label phase 3 study of the bruton's tyrosine kinase inhibitor PCI\u201032765 versus chlorambucil in patients 65 years or older with treatment\u2010na\u00efve chronic lymphocytic leukemia or small lymphocytic lymphoma (RESONATE\u20102)"},{"key":"e_1_2_10_48_1","unstructured":"National Library of Medicine Bethesda MD Pharmacyclics A multicenter phase 2 study of PCI\u201032765 (Ibrutinib) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with 17p deletion"},{"key":"e_1_2_10_49_1","unstructured":"National Library of Medicine Bethesda MD National Cancer Institute (NCI) Ibrutinib in treating patients with relapsed or refractory follicular lymphoma"},{"key":"e_1_2_10_50_1","unstructured":"National Library of Medicine Bethesda MD Jannsen Research & Development LLC A study of pci\u201032765 (Ibrutinib) in patients with refractory follicular lymphoma"},{"key":"e_1_2_10_51_1","unstructured":"National Library of Medicine Bethesda MD Pharmacyclics Multicenter phase 2 study of Bruton's tyrosine kinase inhibitor PCI\u201032765 in relapsed or refractory mantle cell lymphoma"},{"key":"e_1_2_10_52_1","unstructured":"Pharmacyclics A multicenter phase 2 study of the Bruton's tyrosine kinase (Btk) inhibitor PCI\u201032765 in subjects with relapsed or relapsed and refractory multiple myeloma"},{"key":"e_1_2_10_53_1","unstructured":"National Library of Medicine Bethesda MD Janssen Research and Development LLC A randomized controlled open\u2010label multicenter phase 3 study of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib versus temsirolimus in subjects with relapased or refractory mantle cell lymphoma who have received at least one prior therapy"},{"key":"e_1_2_10_54_1","unstructured":"National Library of Medicine Bethesda MD Janssen Research & Development LLC A phase 2 multicenter single\u2010arm study to evaluate the efficacy and safety of single\u2010agent Bruton's tyrosine kinase (BTK) inhibitor ibrutinib in subjects with mantle cell lymphoma who progress after Bortezomib therapy"},{"key":"e_1_2_10_55_1","unstructured":"National Library of Medicine Bethesda MD Janssen Research & Development LLC A study of ibrutinib in combination with bendamustine and rituximab in patiens with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma"},{"key":"e_1_2_10_56_1","unstructured":"National Library of Medicine Bethesda MD Janssen Research & Development LLC A study of the Bruton's tyrosine kinase inhibitor PCI\u201032765 (Ibrutinib) in combination with rituximab cyclophosphamide doxorubicin vincristine and prednisone in patients with newly diagnosed non\u2010germinal center B\u2010cell subtype of diffuse large B\u2010cell lymphoma"},{"key":"e_1_2_10_57_1","unstructured":"National Library of Medicine Bethesda MD Kami Maddocks PCI\u201032765 (Ibrutinib) in treating patients with relapsed or refractory chronic lymphocytic leukemia small lymphocytic lymphoma or B\u2010cell prolymphocytic leukemia"},{"key":"e_1_2_10_58_1","unstructured":"National Library of Medicine Bethesda MD National Heart Lung and Blood Institute (NHLBI) PCI\u201032765 for special cases of chronic lymphocytic leukemia of small lymphocytic lymphoma"},{"issue":"1","key":"e_1_2_10_59_1","article-title":"The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib combine with bendamustine and rituximab is active and tolerable in patients with relapsed\/refractory CLL, interim results of a phase Ib\/II study [abstract 0543]","volume":"97","author":"Brown J","year":"2012","journal-title":"Haematologica"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1366","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1366","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:56:29Z","timestamp":1761047789000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,12]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1002\/phar.1366"],"URL":"https:\/\/doi.org\/10.1002\/phar.1366","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,12]]},"assertion":[{"value":"2013-12-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}